Hayley Virgil | Authors


Enzalutamide/Abiraterone Acetate/Prednisolone Combo in mHSPC Not Recommended

September 11, 2022

Androgen deprivation therapy plus abiraterone acetate and prednisolone resulted in a clinically meaningful overall survival benefit, but this in combination with enzalutamide fell short in patients with metastatic hormone-sensitive prostate cancer.

Benefit of Maintenance Rucaparib in Ovarian Cancer Seen Across Subgroups

September 11, 2022

Maintenance rucaparib (Rubraca) induced a progression-free survival (PFS) improvement in patients with newly diagnosed ovarian cancer compared with placebo, which was also seen across all prespecified subgroups.

Survival Benefit Seen With Frontline Tremelimumab/Durvalumab/Chemo in Some mNSCLC

August 09, 2022

The combination of tremelimumab plus durvalumab and chemotherapy in the first-line elicited survival benefit in patients with metastatic nonsquamous cell non–small cell lung cancer who harbor STK11, KEAP1, and KRAS mutations.